Optimization in the HIV treatment: economic and organizational impact analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide
DOI:
https://doi.org/10.33393/grhta.2025.3292Keywords:
BIC/FTC/TAF, Budget Impact Analysis, HIV, Italian setting, Organizational impactAbstract
Introduction: Given the availability of a growing number of HIV treatment options, it becomes essential to have a clear understanding of the related economic-organizational evidence, to operate informed and conscious choices. The study aims to define the economic and organizational impact related to a consolidated use of Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF), within the Italian National Healthcare Service (NHS), for the treatment of both naïve and experienced HIV individuals.
Materials and methods: A budget impact analysis was developed assuming the NHS perspective and considering a 36-month time horizon. Scenario A, representative of the current situation of consumption of the different therapeutic alternatives (derived from the most update guidelines), was compared with Scenario B, assuming a greater adoption of BIC/FTC/TAF. An organizational impact analysis was conducted to define any advantages for hospitals, devoted to the management of any ART-related adverse events.
Results: The BIA revealed an economic saving of 0.97% (26,040,271.36 €) given a higher penetration rate for BIC/FTC/TAF, for the treatment of HIV individuals assuming ART in Italy. From an organizational perspective, a greater BIC/FTC/TAF administration would generate a reduction in the overall hospital accesses devoted to the management of adverse events, generating an overall saving of 245,938 hours, considering the time spent by the healthcare professionals involved in the care and treatment of individuals with HIV.
Conclusions: BIC/FTC/TAF represent an interesting possibility for the rapid initiation of ART, as well as for switches, being able to optimize the clinical pathway of a patient with HIV, from an economic and organizational perspective.
Downloads
References
Duracinsky M, Herrmann S, Berzins B, et al. The development of PROQOL-HIV: an international instrument to assess the health-related quality of life of persons living with HIV/AIDS. J Acquir Immune Defic Syndr. 2012;59(5):498-505. https://doi.org/10.1097/QAI.0b013e318245cafe PMID:22205438 DOI: https://doi.org/10.1097/QAI.0b013e318245cafe
Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26(3):335-343. https://doi.org/10.1097/QAD.0b013e32834dcec9 PMID:22089374 DOI: https://doi.org/10.1097/QAD.0b013e32834dcec9
Havlir DV, Kendall MA, Ive P, et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482-1491. https://doi.org/10.1056/NEJMoa1013607 PMID:22010914 DOI: https://doi.org/10.1056/NEJMoa1013607
Lee SA, Sinclair E, Hatano H, et al. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One. 2014;9(2):e89444. https://doi.org/10.1371/journal.pone.0089444 PMID:24586783 DOI: https://doi.org/10.1371/journal.pone.0089444
Deeks ED. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs. 2018;78(17):1817-1828. https://doi.org/10.1007/s40265-018-1010-7 PMID:30460547 DOI: https://doi.org/10.1007/s40265-018-1010-7
EMA. Riassunto delle Caratteristiche Tecniche del prodotto. Online https://www.ema.europa.eu/en/documents/product-information/biktarvy-epar-product-information_it.pdf (Accessed September 2024)
Wohl D, Clarke A, Maggiolo F, et al. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 2018;11(5):561-573. https://doi.org/10.1007/s40271-018-0322-8 PMID:29956087 DOI: https://doi.org/10.1007/s40271-018-0322-8
Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063-2072. https://doi.org/10.1016/S0140-6736(17)32299-7 PMID:28867497 DOI: https://doi.org/10.1016/S0140-6736(17)32299-7
Molina J-M, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357-e365. https://doi.org/10.1016/S2352-3018(18)30092-4 PMID:29925489 DOI: https://doi.org/10.1016/S2352-3018(18)30092-4
Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073-2082. https://doi.org/10.1016/S0140-6736(17)32340-1 PMID:28867499 DOI: https://doi.org/10.1016/S0140-6736(17)32340-1
Sax PE, Rockstroh JK, Luetkemeyer AF, et al; GS-US-380–4030 Investigators. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2021;73(2):e485-e493. https://doi.org/10.1093/cid/ciaa988 PMID:32668455 DOI: https://doi.org/10.1093/cid/ciaa988
Butler K, Anderson SJ, Hayward O, et al. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States. J Manag Care Spec Pharm. 2021;27(7):891-903. https://doi.org/10.18553/jmcp.2021.27.7.891 PMID:34185564 DOI: https://doi.org/10.18553/jmcp.2021.27.7.891
Estrada V, Górgolas M, Peña JA, et al. Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain. PharmacoEconom Open. 2022;6(3):415-424. https://doi.org/10.1007/s41669-022-00322-w PMID:35124787 DOI: https://doi.org/10.1007/s41669-022-00322-w
Gill MJ, Powell M, Vu Q, Krentz HB. Economic impact on direct healthcare costs of missing opportunities for diagnosing HIV within healthcare settings. HIV Med. 2021;22(8):723-731. https://doi.org/10.1111/hiv.13121 PMID:33979022 DOI: https://doi.org/10.1111/hiv.13121
Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health. 2007;10(5):336-347. https://doi.org/10.1111/j.1524-4733.2007.00187.x PMID:17888098 DOI: https://doi.org/10.1111/j.1524-4733.2007.00187.x
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Online https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv (Accessed September 2024)
Lombardia R. Direzione Generale Welfare. Percorso diagnostico terapeutico assistenziale (PDTA) del paziente affetto da infezione/malattia HIV/AIDS. Anno 2021. Online https://www.simit.org/images/regioni/lombardia/comunicazioni/Documenti%20Regionali/PDTA%20HIV%20Regione%20Lombardia%202021.pdf (Accessed September 2024)
Shang Z. Use of Delphi in health sciences research: A narrative review. Medicine (Baltimore). 2023 Feb 17;102(7):e32829. doi: 10.1097/MD.0000000000032829 PMID: 36800594 DOI: https://doi.org/10.1097/MD.0000000000032829
D’Achille A. An analysis of healthcare processes through an Activity-based Costing approach.
Economia Aziendale Online, 2019; S 10(1):93-10. http://dx.doi.org/10.13132/2038-5498/10.1.1948
UNAIDS. End Inequalities. End Aids. Global Aids Strategy 2021-2026. 2021. Online https://www.unaids.org/sites/default/files/media_asset/global-AIDS-strategy-2021-2026_en.pdf (Accessed September 2024)
Garagiola E, Foglia E, Ferrario L, et al. HTA and HIV: The Case of Dual NRTI Backbones in the Italian Setting. Int J Environ Res Public Health. 2020;17(23):9010. https://doi.org/10.3390/ijerph17239010 PMID:33287274 DOI: https://doi.org/10.3390/ijerph17239010
Spiegelhalter DJ, Myles JP, Abrams KR. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. 2003. https://doi.org/10.1002/0470092602 DOI: https://doi.org/10.1002/0470092602
Galli M, Borderi M, Viale P. HIV policy in Italy and recommendations across the HIV care continuum. Le Infezioni in Medicina, n. 1, 17-28, 2020 PMID: 32172257
Croce D, Lazzarin A, Rizzardini G, et al. HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy. PLoS One. 2016;11(12):e0168399. https://doi.org/10.1371/journal.pone.0168399 PMID:28030621 DOI: https://doi.org/10.1371/journal.pone.0168399
ISTAT. Indicatori demografici anno 2022. Online https://www.istat.it/it/files/2023/04/indicatori-anno-2022.pdf (Accessed September 2024)
Guinan K, Mathurin K, Lachain J. Economic Impact of Rapid Treatment Initiation of HIV with Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from a Canadian Healthcare Perspective. Value Health. 2023; S26 (6): S184-S185. https://doi.org/10.1016/j.jval.2023.03.994 DOI: https://doi.org/10.1016/j.jval.2023.03.994
Kolakowska A, Maresca AF, Collins IJ, Cailhol J. Update on Adverse Effects of HIV Integrase Inhibitors. Curr Treat Options Infect Dis. 2019;11(4):372-387. https://doi.org/10.1007/s40506-019-00203-7 PMID:33380904 DOI: https://doi.org/10.1007/s40506-019-00203-7
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2025-02-03
Published 2025-02-26
